Evidence map›Paper›PMID 39301750›Full record

ArticleCancer2025

Identification of HEPACAM2 as a novel and specific marker of small cell carcinoma.

Karen S McColl, Abhishek Ajay, Han Wang, Gary M Wildey, Suzy Yoon, Brandon Grubb, Shelby R Kopp, Peronne L Joseph, Michela Saviana, Giulia Romano and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Karen S McCollDivision of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Abhishek AjayDivision of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Han WangDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.
Gary M WildeyDivision of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0001-7105-1313
Suzy YoonDivision of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Brandon GrubbDivision of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Shelby R KoppDivision of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Peronne L JosephDivision of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Michela SavianaDivision of Pulmonary Diseases and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Giulia RomanoDivision of Pulmonary Diseases and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Patrick Nana-SinkamDivision of Pulmonary Diseases and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Craig D PeacockDivision of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0001-8139-8628
Zixi YunDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.
Wadad MneimnehRobert J. Tomsich Pathology & Laboratory Medicine Institute, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Minh LamDivision of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-1373-4241
Masaru MiyagiDepartment of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA.
Hung-Ying KaoDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA.
Afshin DowlatiDivision of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-4535-6839

Funding

Extracellular Vesicles in Small Cell Lung Cancer Early DetectionU01CA213330 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI LEE, LY JAMES, NANASINKAM, SERGE PATRICK · 2017 to 2021
$2.7M
Department of Defense LC160523NCI NIH HHS 5U01CA213330NCI NIH HHS U01 CA213330Seidman Cancer Center
6 · The paper itself

Abstract

backgroundSmall cell lung cancer (SCLC) is the most aggressive neuroendocrine lung cancer, with a dismal 5-year survival rate. No reliable biomarkers or imaging are available for early SCLC detection. In a search for a specific marker of SCLC, this study identified that hepatocyte cell adhesion molecule 2 (HEPACAM2), a member of the immunoglobulin-like superfamily, is highly and specifically expressed in SCLC.

methodsThis study investigated HEPACAM2 expression in patients with SCLC via RNA sequencing and evaluated its relationship to progression-free survival (PFS) and overall survival (OS). Immunofluorescence microscopy was used to assess the cellular location of HEPACAM2 and to conduct in vitro and in vivo studies to understand its expression and functional significance. These findings were integrated with databases of patients with SCLC.

resultsHEPACAM2 is highly expressed and specific to SCLC. HEPACAM2 levels are inversely correlated with PFS and OS in patients with SCLC and are expressed at all stages. Moreover, HEPACAM2 messenger RNA and its peptides can be detected in the secretomes in cell lines. Positively correlated with ASCL1 expression in SCLC tumors, HEPACAM2 is localized primarily to the plasma membrane and linked to extracellular matrix signaling and cellular migration. A loss of HEPACAM2 in SCLC cells attenuated ASCL1 and MYC expression. Consistent with clinical data, in vitro and in vivo studies suggested that HEPACAM2 promotes cancer cell growth.

conclusionsWith its remarkable specificity, high expression, presence in early disease, and extracellular secretion, HEPACAM2 could be a potential diagnostic cell surface biomarker for early SCLC detection. These findings warrant further investigation into its role in the pathobiology of SCLC.

Indexed as

Biomarkers, TumorLung NeoplasmsSmall Cell Lung CarcinomaAgedAnimalsBasic Helix-Loop-Helix ProteinsCell Cycle ProteinsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMiddle AgedBasic Helix-Loop-Helix ProteinsBiomarkers, TumorCell Cycle ProteinsHEPACAM protein, humanbiomarkergene expressionHEPACAM2small cell lung cancer

Identifiers

PMID39301750
PMCPMC11694165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.